A promising first-in-class approach for schizophrenia

Individuals with schizophrenia have low levels of D-serine, a key neurotransmitter that activates the NMDA receptor in the brain that is widely believed to play a key role in schizophrenia. Even though academic studies suggested D-serine might be a compelling adjunctive treatment for schizophrenia, the development of D-serine has historically been limited due to potential renal safety concerns. Concert designed CTP-692 to attain the broad efficacy observed with D-serine with a potentially improved safety profile.

CTP-692 is an investigational deuterium-modified form of D-serine with the potential to more broadly treat the symptoms of schizophrenia than has been previously possible with an entirely new mechanism of action. CTP-692 will be initially developed as an adjunctive therapy administered in addition to standard antipsychotic medicines with the potential to improve positive and negative symptoms as well as cognitive function in patients with schizophrenia.

Broadening the scope of treating schizophrenia

Schizophrenia is a chronic and devastating neuropsychiatric disorder that affects nearly 1% of the world’s population. Though existing antipsychotic medicines have made great strides in impacting the most visible psychotic symptoms that are hallmarks of the disease, other negative and cognitive symptoms of schizophrenia are not adequately treated in many patients. Concert is exploring an approach to amplify and broaden the effects of current medicines with a new, adjunctive treatment to improve outcomes for patients.

CTP-692 Clinical Path: An adjunctive, broad spectrum treatment

Concert is developing CTP-692 as an adjunctive treatment for schizophrenia, to be administered in addition to standard antipsychotic medicines. The clinical program will evaluate the potential of CTP-692 to address a broad spectrum of symptoms of schizophrenia and offer a possible new approach for improving treatment for schizophrenia patients.

CTP-692 has been well tolerated in the clinical studies to-date:

  • In preclinical evaluation, Concert found that CTP-692 improved renal safety compared to non-deuterated d-serine, reflected by serum creatinine and blood urea nitrogen levels.
  • In Phase 1 clinical trials evaluating CTP-692, Concert reported positive results:
    • The safety assessments in the single- and multiple-ascending dose trials in healthy volunteers showed that CTP-692 was well tolerated over all the dose ranges tested, and in contrast to previous reports for D-serine, blood levels of CTP-692 were highly consistent across individuals.
    • Importantly, key blood and urine markers of kidney function did not indicate any signs of renal impairment.

Concert is currently conducting a Phase 2 trial with CTP-692 in patients with schizophrenia.

CTP-692 in the Clinic


Phase 2 Study as an Adjunctive Treatment in Adults With Schizophrenia

To learn more about Concert’s sponsored clinical trials, please visit clinicaltrials.gov:

Back to Top